Logo image of BNTC

BENITEC BIOPHARMA INC (BNTC) Stock Fundamental Analysis

NASDAQ:BNTC - Nasdaq - US08205P2092 - Common Stock - Currency: USD

12.99  0 (0%)

Fundamental Rating

3

BNTC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. BNTC has a great financial health rating, but its profitability evaluates not so good. BNTC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BNTC had negative earnings in the past year.
In the past year BNTC has reported a negative cash flow from operations.
In the past 5 years BNTC always reported negative net income.
BNTC had a negative operating cash flow in each of the past 5 years.
BNTC Yearly Net Income VS EBIT VS OCF VS FCFBNTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

BNTC's Return On Assets of -27.87% is fine compared to the rest of the industry. BNTC outperforms 69.81% of its industry peers.
BNTC has a better Return On Equity (-29.01%) than 78.88% of its industry peers.
Industry RankSector Rank
ROA -27.87%
ROE -29.01%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BNTC Yearly ROA, ROE, ROICBNTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

1.3 Margins

BNTC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BNTC Yearly Profit, Operating, Gross MarginsBNTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

More info and screens

8

2. Health

2.1 Basic Checks

BNTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
BNTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BNTC Yearly Shares OutstandingBNTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
BNTC Yearly Total Debt VS Total AssetsBNTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

An Altman-Z score of 55.00 indicates that BNTC is not in any danger for bankruptcy at the moment.
BNTC's Altman-Z score of 55.00 is amongst the best of the industry. BNTC outperforms 98.43% of its industry peers.
BNTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 55
ROIC/WACCN/A
WACC10.57%
BNTC Yearly LT Debt VS Equity VS FCFBNTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 25.48 indicates that BNTC has no problem at all paying its short term obligations.
The Current ratio of BNTC (25.48) is better than 97.03% of its industry peers.
A Quick Ratio of 25.48 indicates that BNTC has no problem at all paying its short term obligations.
BNTC's Quick ratio of 25.48 is amongst the best of the industry. BNTC outperforms 97.03% of its industry peers.
Industry RankSector Rank
Current Ratio 25.48
Quick Ratio 25.48
BNTC Yearly Current Assets VS Current LiabilitesBNTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

BNTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.58%, which is quite impressive.
BNTC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)65.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.5%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.98% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y82.9%
EPS Next 2Y31.84%
EPS Next 3Y19.98%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BNTC Yearly Revenue VS EstimatesBNTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
BNTC Yearly EPS VS EstimatesBNTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BNTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BNTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNTC Price Earnings VS Forward Price EarningsBNTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNTC Per share dataBNTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

BNTC's earnings are expected to grow with 19.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.84%
EPS Next 3Y19.98%

More info and screens

0

5. Dividend

5.1 Amount

BNTC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BENITEC BIOPHARMA INC

NASDAQ:BNTC (3/7/2025, 8:08:10 PM)

12.99

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-14 2025-02-14/bmo
Earnings (Next)05-12 2025-05-12/bmo
Inst Owners86.09%
Inst Owner Change38.52%
Ins Owners0.53%
Ins Owner Change22.74%
Market Cap304.62M
Analysts87.69
Price Target25.94 (99.69%)
Short Float %0.67%
Short Ratio3.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.2%
Min EPS beat(2)14.44%
Max EPS beat(2)57.97%
EPS beat(4)2
Avg EPS beat(4)-49.63%
Min EPS beat(4)-165.05%
Max EPS beat(4)57.97%
EPS beat(8)4
Avg EPS beat(8)-144.64%
EPS beat(12)5
Avg EPS beat(12)-124.22%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)5.95%
EPS NQ rev (1m)56.27%
EPS NQ rev (3m)67.09%
EPS NY rev (1m)49.97%
EPS NY rev (3m)61.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.01
P/tB 4.01
EV/EBITDA N/A
EPS(TTM)-3.77
EYN/A
EPS(NY)-2.19
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS0
BVpS3.24
TBVpS3.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.87%
ROE -29.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 25.48
Quick Ratio 25.48
Altman-Z 55
F-Score5
WACC10.57%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.5%
EPS Next Y82.9%
EPS Next 2Y31.84%
EPS Next 3Y19.98%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.84%
EBIT Next 3Y35.42%
EBIT Next 5YN/A
FCF growth 1Y-20.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.7%
OCF growth 3YN/A
OCF growth 5YN/A